KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Long-Term Debt Repayments (2018 - 2022)

Gsk has reported Long-Term Debt Repayments over the past 7 years, most recently at $12.4 billion for Q1 2022.

  • For Q1 2022, Long-Term Debt Repayments changed N/A year-over-year to $12.4 billion; the TTM value through Mar 2022 reached $14.3 billion, changed N/A, while the annual FY2020 figure was $4.4 billion, 29.35% down from the prior year.
  • Long-Term Debt Repayments for Q1 2022 was $12.4 billion at Gsk, up from -$4.4 billion in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $12.4 billion in Q1 2022 and troughed at -$13.0 billion in Q4 2018.
  • A 4-year average of $1.1 billion and a median of $3.0 billion in 2020 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 125.65% in 2019 and later plummeted 230.12% in 2020.
  • Year by year, Long-Term Debt Repayments stood at -$13.0 billion in 2018, then skyrocketed by 125.65% to $3.3 billion in 2019, then plummeted by 230.12% to -$4.4 billion in 2020, then surged by 383.63% to $12.4 billion in 2022.
  • Business Quant data shows Long-Term Debt Repayments for GSK at $12.4 billion in Q1 2022, -$4.4 billion in Q4 2020, and $3.0 billion in Q3 2020.